secwatch.observer — SEC 8-K summary
======================================

Issuer:     BICYCLE THERAPEUTICS PLC (BCYC)
CIK:        0001761612
Form:       8-K
Filed at:   2024-10-23T23:59:59+00:00
Accession:  0001104659-24-110749
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

First human imaging data validate MT1-MMP BRC radiopharmaceutical potential; strategy outlined
--------------------------------------------------------------------------------

- First human PET/CT data for gallium-68-labelled MT1-MMP BRC show tracer uptake in lung cancer primary and metastases consistent with FDG imaging.
- Preclinical data demonstrate BRC biodistribution optimized to maintain high tumor uptake while significantly reducing kidney retention.
- Company selects EphA2 as second BRC target; signs letter of intent with Eckert & Ziegler for isotope supply and manufacturing.
- CEO Kevin Lee highlights strategy to pursue novel targets with first-in-class radiopharmaceuticals using Bicycle platform.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1761612/000110465924110749/0001104659-24-110749-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1761612/000110465924110749/tm2426653d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-110749

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer